Show simple item record

dc.contributor.authorTruman, Lucy A.
dc.contributor.authorPekalski, Marcin L.
dc.contributor.authorKareclas, Paula
dc.contributor.authorEvangelou, Marina
dc.contributor.authorWalker, Neil M.
dc.contributor.authorHowlett, James
dc.contributor.authorMander, Adrian P.
dc.contributor.authorKennet, Jane
dc.contributor.authorWicker, Linda S.
dc.contributor.authorBond, Simon
dc.contributor.authorTodd, John A.
dc.contributor.authorWaldron-Lynch, Frank
dc.date.accessioned2019-10-25T21:01:48Z
dc.date.available2019-10-25T21:01:48Z
dc.date.created2017-09-28 23:44
dc.date.issued2015-09-16
dc.identifieroai:www.repository.cam.ac.uk:1810/250599
dc.identifierhttps://www.repository.cam.ac.uk/handle/1810/250599
dc.identifier.urihttp://hdl.handle.net/20.500.12424/1528386
dc.description.abstractThis is the final version of the article. It was first available from BMJ via http://dx.doi.org/10.1136/bmjopen-2015-009799
dc.description.abstractIntroduction: Type 1 diabetes (T1D) is caused by autoimmune destruction of the insulin-producing β cells in the pancreatic islets, leading to insulin deficiency and hyperglycaemia. Genetic analyses indicate that deficiencies in the interleukin-2 (IL-2) pathway in immune activation and tolerance predispose to T1D, in particular in the polymorphic expression of the IL-2 receptor α chain (CD25) on T lymphocytes. Replacement of physiological doses of IL-2 may help to maintain self-tolerance and prevent further autoimmunity by specifically enhancing the suppressive function of CD4+ T regulatory cells (Tregs), which limit the activation of auto-reactive T effector cells (Teffs). In this experimental medicine study, we use an adaptive trial design to determine the optimal dosing regimen for administering IL-2 to improve Treg function whilst limiting activation of Teffs in patients with T1D.
 
 Method and analysis: The Adaptive study of IL-2 dose frequency on Tregs in type 1 diabetes (DILfrequency) is a mechanistic, non-randomised, repeat dose open-label, response-adaptive study of 36 participants with recently diagnosed T1D. The aim is to establish the optimal dose and frequency of administration of ultra-low dose IL-2. The three co-primary objectives are: to increase Treg frequencies within the physiological normal range, to increase CD25 expression on Tregs, whilst not causing increases in CD4+ Teff frequencies. DILfrequency is designed to have an initial learning phase in which 12 participants are allocated to six different doses and frequencies followed by an interim statistical analysis. After examining the results of the learning phase, the Dose and Frequency Committee will select the optimal targets of Treg frequency, Treg CD25 expression and lack of Teff proliferation, for the remaining 24 participants. A confirming phase comprising three groups of participants will be treated with Proleukin consecutively. Each dose and frequency selected will based on analysis of all data collected from the previous groups. 
 
 Ethics and dissemination: DILfrequency was approved by UK ethics (REC reference 14/EE/1057). Study results will be published.
 
 Trial registration numbers: NCT02265809, ISRCTN40319192, CRN17571.
 
 Strengths and limitations of this study:
 - This non randomised, repeat dose, open label, response adaptive study has three co-primary objectives to determine the optimal dose and frequency of interleukin-2 administration in patients with type 1 diabetes to preferentially stimulate T regulatory cells over T effector cells.
 - The study is not designed to test the effects of interleukin-2 on pancreatic beta-cell function and insulin secretion.
dc.description.abstractThis work is funded by The Sir Jules Thorn Award for Biomedical Research 2013 (13/JTA), the JDRF (9-2011-253), the Wellcome Trust (091157) and the National Institute for Health Research Cambridge Biomedical Research Centre. The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (100140). AM was supported by the Medical Research Council [grant number G0800860] and the National Institute for Health Research Cambridge Biomedical Research Centre.
dc.languageen
dc.language.isoeng
dc.publisherBMJ Group
dc.publisherBMJ Open
dc.rightsCreative Commons Attribution 4.0 International License
dc.titleProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open label, response-adaptive study
dc.typeArticle
ge.collectioncodeOAIDATA
ge.dataimportlabelOAI metadata object
ge.identifier.legacyglobethics:11594468
ge.identifier.permalinkhttps://www.globethics.net/gel/11594468
ge.lastmodificationdate2017-09-28 23:44
ge.lastmodificationuseradmin@pointsoftware.ch (import)
ge.submissions0
ge.oai.exportid148650
ge.oai.repositoryid1300
ge.oai.setnameUniversity Library Projects
ge.oai.setnameCambridge University libraries
ge.oai.setnameOther Communities
ge.oai.setnameCambridge Institute for Medical Research
ge.oai.setnameSchool of Clinical Medicine
ge.oai.setnameSymplectic mapped items for data match
ge.oai.setnameScholarly Works - Cambridge Institute for Medical Research
ge.oai.setspeccom_1810_229649
ge.oai.setspeccom_1810_751
ge.oai.setspeccom_1810_256067
ge.oai.setspeccom_1810_245928
ge.oai.setspeccom_1810_34581
ge.oai.setspeccol_1810_265264
ge.oai.setspeccol_1810_245929
ge.oai.streamid2
ge.setnameGlobeEthicsLib
ge.setspecglobeethicslib
ge.linkhttps://www.repository.cam.ac.uk/handle/1810/250599


This item appears in the following Collection(s)

Show simple item record